Skip to main content

Table 2 Comparison of the baseline data of the clinicoradiological data

From: Using pre-operative radiomics to predict microvascular invasion of hepatocellular carcinoma based on Gd-EOB-DTPA enhanced MRI

 

Training set (n = 115)

Validation set (n = 50)

P*

MVI-negative (n = 81)

MVI-positive (n = 34)

P value

MVI-negative (n = 35)

MVI-positive (n = 15)

P value

Sex

  

1.00

  

0.30

0.65

 0, Female

32 (39.5)

13 (38.2)

 

14 (40.0)

3 (20.0)

  

 1, Male

49 (60.5)

21 (61.8)

 

21 (60.0)

12 (80.0)

  

Multifocality

  

1.00

  

1.00

0.55

 0, No

69 (85.2)

29 (85.3)

 

28 (80.0)

12 (80.0)

  

 1, Yes

12 (14.8)

5 (14.7)

 

7 (20.0)

3 (20.0)

  

Cirrhosis

       

 0, No

5 (6.2)

3 (8.8)

0.92

2 (5.7)

2 (13.3)

0.73

0.47

 1, Yes

76 (93.8)

31 (91.2)

 

33 (94.3)

13 (86.7)

  

HBsAg

  

0.64

  

0.93

0.96

 0, Negative

14 (17.3)

4 (11.8)

 

5 (14.3)

3 (20.0)

  

 1, Positive

67 (82.7)

30 (88.2)

 

30 (85.7)

12 (80.0)

  

Tumour signal on T2WI

  

0.06

  

1.00

0.67

 0, Homogeneous

15 (18.5)

1 (2.9)

 

4 (11.4)

1 (6.7)

  

 1, Heterogeneous

66 (81.5)

33 (97.1)

 

31 (88.6)

14 (93.3)

  

Peritumoural enhancement

  

0.65

  

0.05

0.45

 0, No

71 (87.7)

28 (82.4)

 

31 (88.6)

9 (60.0)

  

 1, Yes

10 (12.3)

6 (17.6)

 

4 (11.4)

6 (40.0)

  

Tumour capsule

  

 < 0.001

  

0.34

0.17

 0, Absent

25 (30.9)

8 (23.5)

 

11 (31.4)

3 (20.0)

  

 1, Incomplete

7 ( 8.6)

15 (44.1)

 

9 (25.7)

7 (46.7)

  

 2, Complete

49 (60.5)

11 (32.4)

 

15 (42.9)

5 (33.3)

  

Tumour margin

  

 < 0.001

  

0.10

0.07

 0, Smooth

62 (76.5)

12 (35.3)

 

20 (57.1)

4 (26.7)

  

 1, Non-smooth

19 (23.5)

22 (64.7)

 

15 (42.9)

11 (73.3)

  

Peritumoural hypointensity

  

 < 0.001

  

0.01

0.51

 0, No

75 (92.6)

17 (50.0)

 

30 (85.7)

7 (46.7)

  

 1, Yes

6 (7.4)

17 (50.0)

 

5 (14.3)

8 (53.3)

  

Age

58.00 [52.00, 65.00]

60.00 [51.50, 64.00]

0.95

57.00 [50.00, 63.50]

55.00 [52.50, 63.50]

0.76

0.67

Tumour size

2.18 [1.60, 3.18]

3.68 [2.70, 5.79]

 < 0.001

2.68 [1.95, 3.65]

4.20 [3.30, 5.33]

0.01

0.90

AFP

8.19 [3.32, 89.75]

25.98 [3.50, 183.14]

0.24

50.29 [6.24, 225.46]

22.14 [6.17, 82.26]

0.62

0.52

ALT

30.00 [22.00, 46.00]

28.50 [22.25, 46.00]

0.62

30.00 [23.50, 44.00]

30.00 [17.50, 46.50]

0.66

0.78

AST

36.00 [27.00, 50.00]

35.50 [26.50, 45.00]

0.58

38.00 [27.00, 53.50]

32.00 [26.00, 38.00]

0.22

0.88

ALB

42.10 [38.80, 44.30]

42.05 [38.25, 44.85]

0.69

40.60 [37.40, 44.55]

42.50 [39.75, 44.70]

0.44

0.81

TBIL

15.90 [12.70, 21.30]

15.40 [11.88, 18.78]

0.27

15.00 [11.95, 22.75]

16.50 [12.30, 20.95]

0.90

0.68

DBIL

5.30 [4.10, 7.10]

4.55 [4.03, 6.68]

0.26

5.40 [3.85, 7.90]

6.30 [3.40, 7.30]

0.97

0.43

PLT

111.00 [69.00, 144.00]

109.50 [82.75, 146.75]

0.32

107.00 [80.50, 127.00]

145.00 [102.50, 207.00]

0.04

0.34

PT

12.50 [11.60, 13.40]

11.80 [11.20, 12.33]

0.04

12.60 [11.90, 13.40]

11.90 [11.65, 12.40]

0.11

0.13

INR

1.07 [0.99, 1.17]

1.01 [0.96, 1.05]

0.02

1.08 [1.02, 1.15]

1.05 [1.00, 1.08]

0.15

0.45

  1. P*, P value for the test between the training set and the validation set
  2. MVI microvascular invasion, HBsAg hepatitis B surface antigen, T2WI T2-weighted imaging, AFP alpha-fetoprotein, ALT alanine-aminotransferase, AST aspartate-aminotransferase, ALB albumin, TBIL total bilirubin, DBIL direct bilirubin, PLT platelets, PT prothrombin time, INR international normalised ratio
Back to article page

BMC Medical Imaging

ISSN: 1471-2342

Contact us